LP
SION

Longaeva Partners’s Sionna Therapeutics SION Stock Holding History

Longaeva Partners’s Portfolio SION Stock Details SION Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$509K Sell
12,693
-67,036
-84% -$2.56M 0.02% 185
2025
Q4 		$3.28M Buy
79,729
+18,272
+30% +$693K 0.28% 81
2025
Q3 		$1.81M Buy
+61,457
New +$1.34M 0.26% 53

Other funds holding SION

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Longaeva Partners's SION Position: Q1 2026 in Review

Longaeva Partners reduced its Sionna Therapeutics (SION) stake by 84% in Q1 2026, selling an estimated $2.56M and leaving 12,693 shares worth $509K. The position accounts for 0.02% of the portfolio, ranked #185.

Longaeva Partners first reported a position in SION in Q3 2025 and has held it in 3 quarters since. The position peaked at $3.28M in Q4 2025. 122 funds tracked by Wall St. Rank hold SION as of Q1 2026.

  • Longaeva Partners held 12,693 shares of Sionna Therapeutics worth $509K as of Q1 2026.
  • Longaeva Partners sold 67,036 Sionna Therapeutics shares in Q1 2026, an estimated $2.56M.
  • Sionna Therapeutics made up 0.02% of Longaeva Partners's portfolio in Q1 2026, its #185 holding.
  • Longaeva Partners first reported a position in Sionna Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Longaeva Partners's Sionna Therapeutics position peaked at $3.28M in Q4 2025.
  • 122 funds tracked by Wall St. Rank held Sionna Therapeutics as of Q1 2026.

Based on Longaeva Partners's 13F filing for Q1 2026, filed 15 May 2026.